Ben Youngblood

The paper analyzes bone marrow microenvironment changes in HMA-resistant MDS patients treated with guadecitabine and atezolizumab, finding that long-term survivors show reduced immunosuppressive monocytes and expanded effector lymphocytes.

This paper demonstrates that bioPROTACs can reprogram CAR T-cells by targeting DNMT3A, offering a tunable alternative to gene editing for enhancing T-cell function.

Maternal immune activation causes Treg deficiency in offspring, leading to brain inflammation and autism-like behaviors, which can be reversed by Treg stimulation.